Ocugen, Inc. scheduled a special virtual stockholder meeting for September 21, 2026. The board of directors unanimously recommended increasing authorized common shares from 390 million to 640 million. This amendment adds 250 million shares to the company’s charter.
The expansion provides flexibility for future equity, convertible debt, and strategic business combinations. The move specifically supports $130 million in 6.75% convertible senior notes due in 2034. Ocugen requires these additional shares to cover the maximum potential conversion of the debt.
Capital raised will fund a clinical pipeline targeting three Biologics License Application (BLA) submissions by 2028. The board intends for the additional shares to also enable potential collaborations and future strategic growth.